NCT01804816

Brief Summary

Acupuncture treatment may improve the cardiac function and the quality of life in heart failure patients. These effects may be related to the inhibition of sympathetic activity and/or increased vagal function. The suppression of inflammatory reaction with acupuncture treatment may also be associated with these outcomes. Specific aims include:

  1. 1.To evaluate the effect of acupuncture treatment on human cardiac sympathetic/vagal activity
  2. 2.To evaluate the effect of acupuncture treatment on cardiac function and functional capacity
  3. 3.To evaluate the general health score of the quality-of-life with acupuncture treatment
  4. 4.To explore the mechanism of acupuncture treatment on inflammation and nitrative stress in heart failure patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2013

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 5, 2013

Completed
2 months until next milestone

Study Start

First participant enrolled

May 13, 2013

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 9, 2015

Completed
4.2 years until next milestone

Results Posted

Study results publicly available

March 29, 2019

Completed
2.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

November 4, 2025

Status Verified

October 1, 2025

Enrollment Period

1.7 years

First QC Date

March 4, 2013

Results QC Date

June 5, 2018

Last Update Submit

October 14, 2025

Conditions

Keywords

Chronic Heart FailureHeart Failure

Outcome Measures

Primary Outcomes (2)

  • Change in Cardiac Function: LVEF

    Left ventricular ejection fraction (LVEF) percentage was measured at baseline, after 5 weeks of no treatment and just prior to acupuncture treatment, and after 5 weeks of acupuncture treatments.

    Baseline, Week 7, Week 13

  • Change in 6-Minute Walk Distance

    Baseline, Week 7, Week 13

Secondary Outcomes (1)

  • Change in Quality of Life (QOL)

    Baseline, Week 7, Week 13

Study Arms (2)

Acupuncture

EXPERIMENTAL

10 standardized verum acupuncture (VA) sessions twice a week, over 5 weeks. The 5 weeks of acupuncture were scheduled after the period of no acupuncture for each subject.

Procedure: Acupuncture

No Acupuncture

PLACEBO COMPARATOR

No acupuncture treatment or other study intervention over 5 weeks. All subjects had a 5 week period of "no acupuncture" prior to the 5 weeks of acupuncture sessions.

Other: No Intervention

Interventions

AcupuncturePROCEDURE

Standardized acupuncture administration for 10 sessions.

Acupuncture

No intervention during this period. This was a control period. Each subject acted as their own control.

No Acupuncture

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 21 years
  • Congestive Heart Failure (CHF), New York Heart Association (NYHA) class II-III, Left Ventricular Eject Fraction (LVEF) ≤40%
  • All patients will have sinus rhythm and compensate with individually optimized standard heart failure medications. Routine medications will be continued during the study period
  • Able and willing to give informed consent or comply with study procedures.

You may not qualify if:

  • Acupuncture treatment within 3 months before the beginning of the study
  • Presents with cutaneous eczema at potential acupoints
  • Have a history of major bleeding or increased propensity of excessive bleeding due to platelet dysfunction
  • Currently taking anti-coagulants (e.g. warfarin)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

Related Publications (4)

  • Middlekauff HR, Hui K, Yu JL, Hamilton MA, Fonarow GC, Moriguchi J, Maclellan WR, Hage A. Acupuncture inhibits sympathetic activation during mental stress in advanced heart failure patients. J Card Fail. 2002 Dec;8(6):399-406. doi: 10.1054/jcaf.2002.129656.

    PMID: 12528093BACKGROUND
  • Kurono Y, Minagawa M, Ishigami T, Yamada A, Kakamu T, Hayano J. Acupuncture to Danzhong but not to Zhongting increases the cardiac vagal component of heart rate variability. Auton Neurosci. 2011 Apr 26;161(1-2):116-20. doi: 10.1016/j.autneu.2010.12.003. Epub 2011 Jan 7.

    PMID: 21216208BACKGROUND
  • Deng YJ, Liang WX, Cheng SY. [Influence of acupoint-catgut-implantation on blood pressure and cardiac function in chronic congestive heart failure rats]. Zhen Ci Yan Jiu. 2011 Feb;36(1):40-5. Chinese.

    PMID: 21585058BACKGROUND
  • Kristen AV, Schuhmacher B, Strych K, Lossnitzer D, Friederich HC, Hilbel T, Haass M, Katus HA, Schneider A, Streitberger KM, Backs J. Acupuncture improves exercise tolerance of patients with heart failure: a placebo-controlled pilot study. Heart. 2010 Sep;96(17):1396-400. doi: 10.1136/hrt.2009.187930. Epub 2010 Jun 15.

    PMID: 20554511BACKGROUND

MeSH Terms

Conditions

Heart Failure

Interventions

Acupuncture Therapy

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Complementary TherapiesTherapeutics

Limitations and Caveats

These results should be interpreted with caution. With only 10 subjects, the study may be under-powered to detect a significant difference.

Results Point of Contact

Title
Dr. W.H. Wilson Tang, MD
Organization
Cleveland Clinic Foundation

Study Officials

  • W.H. Wilson Tang, MD

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR
  • Yanming Huang, MD PhD

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Staff Cellular and Molecular Medicine and Cardiovascular Medicine

Study Record Dates

First Submitted

March 4, 2013

First Posted

March 5, 2013

Study Start

May 13, 2013

Primary Completion

January 9, 2015

Study Completion

December 1, 2021

Last Updated

November 4, 2025

Results First Posted

March 29, 2019

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

There is no plan to make individual patient data available.

Locations